Blog

4
Feb

Biofortuna supports World Cancer Day

We are proud to support the UICC’s World Cancer Day initiative

20
Jan

Biofortuna shortlisted for 2020 Bionow awards.

We are delighted to share the news that we have been shortlisted for the 2020 BioNow awards.

10
Dec

Biofortuna sets a new production record.

Biofortuna sees record production levels across November and December

12
Jun

Biofortuna appointed as CMO for QuantuMDx CE–marked assay

Biofortuna has provided assay development and manufacturing support to QuantuMDx Group Limited to assist in the manufacturing scale-up, regulatory approval and launch of their rapid, sensitive SARS-CoV-2 test.

18
Mar

Coronavirus Update from Biofortuna

In light of the current situation with COVID-19, we would like to take this opportunity to assure you that plans have been put into place to ensure business continuity at Biofortuna.

7
Jun

Biofortuna – your outsourcing partner of choice.

Having developed over 100 assays across a range of diverse applications, let Biofortuna be your outsourcing partner of choice. Our FDA registered and ISO 13485 certified manufacturing facilities allow us to take your project from concept through to full commercial production and to market. Contact us now to discuss your requirements.

25
Jul

Biofortuna unveils ampDRY™ air-dried master mix

Biofortuna (Liverpool, UK) – the international IVD contract research and contract manufacturing company – will be launching ampDRY™, its patent pending stabilised master mix for PCR applications, at the AACC Annual Scientific Meeting and Clinical Lab Expo in Chicago, July 29 to August 2. ampDRY hotstart master mix has been developed to enable complete end-stage or real-time PCR assays to

Read more

15
Aug

Biofortuna closes £1.6M funding round

Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has raised £1.6M in its latest funding round. The new funding –supported by current investor Foresight VCTs and members of the senior management team – will allow the company to take its ReadyPlex™ rapid blood group genotyping assays into clinical trials and commercialisation, as well as

Read more

24
Jan

Biofortuna expands its immunoassay development and manufacturing services

Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, development and manufacture. The company has made a significant investment in its production capabilities to include plate coating, washing, drying and quality control, creating an exceptional manufacturing suite for immunoassay kits. Biofortuna already has extensive experience in immunoassay development, and this expansion has been driven

Read more

8
Jul

Biofortuna FDA Inspection Completed Successfully

Biofortuna have successfully completed an FDA site inspection to retain their FDA registered manufacturing site status. The inspection was carried out over several days in which the FDA thoroughly reviewed Biofortuna’s manufacturing, quality control and quality assurance procedures. Biofortuna manufactures 510k approved IVD kits for sale in the US for their molecular diagnostics division. An increasing number of contract service

Read more